Watchlist For March 14: ALZM, USAT, STEM

Stanford Management Ltd (OTC:ALZM) acquired Organ Transport Systems from
Healthcare of Today in an all-stock transaction. The acquisition of OTS serves
as the first of several planned acquisitions by Allezoe Medical Holdings in the
field of medical device development, manufacturing and related services. Michael
Holder, President, CEO and Director of OTS, and Hyman White, Secretary,
Treasurer and Director of OTS, have been appointed to the Board of Directors of
ALZM as result of the acquisition. Mr. Holder will serve as the CEO of Allezoe
and Mr. White as its Secretary and Treasurer. Stanford Management stock is
currently trading at $1.14. The stock is up 10.68 percent from its previous
close. Stanford Management stock touched the high of $1.15 and lowest price in
today's session is $1.08. The company stock has traded in the range of $0.35
and $1.20 during the past 52 weeks. The company's market cap is $60.00
million. USA Technologies, Inc. ( NASDAQ:USAT ) signed a securities purchase
agreement with institutional investors to purchase $10.7 million of common stock
in a private placement. The company will sell an aggregate of 5,200,000 shares
of its common stock at $2.064 per share and warrants to purchase up to 3,900,000
additional shares in the aggregate of its common stock as per the agreement. The
warrants will be exercisable at an exercise price of $2.6058 per share and will
have a five-year term commencing on the initial exercisability date. The
offering is expected to close on or before March 24, 2011. USA Technologies
stock is currently trading at $2.14. The stock is down 17.05 percent from its
previous close. USA Technologies shares touched the high of $2.30 and lowest
price in today's session is $2.08. The company stock has traded in the range
of $0.46 and $2.75 during the past 52 weeks. The company's market cap is
$56.19 million. StemCells, Inc. ( NASDAQ:STEM ) reported a wider loss for the
fourth quarter, primarily due to an increase in fair value of warrant liability.
The company reported fourth quarter net loss of $9.0 million or $0.07 per share,
increased than the loss of $5.2 million or $0.05 per share for the year-ago
quarter. The revenue for the quarter increased 67 percent to $699,000 from
$418,000 last year, resulting from the receipt of a milestone payment from a
licensee, as well as higher product sales revenue from the companys SC Proven
line of media and reagents. The loss from operations for the quarter reduced to
$7.7 million from $8.0 million last year. For the full year, the company
reported a net loss of $25.2 million or $0.20 per share as compared with a net
loss of $27.0 million or $0.25 per share for 2009. The revenue increased 44
percent to $1.4 million from $1.0 million reported in 2009. StemCells stock is
currently trading at $0.860. The stock is up 6.03 percent from its previous
close. StemCells stock touched the high of $0.87 and lowest price in today's
session is $0.82. The company stock has traded in the range of $0.75 and $1.27
during the past 52 weeks. The company's market cap is $105.25 million.